The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement

Authors:

Abstract
No abstract available
Funding Information
  • U.S. Food and Drug Administration (5U18FD005320‐05)
  • American Society of Transplantation
  • Astellas Pharma US
  • Bristol-Myers Squibb
  • Novartis
  • CSL Behring
  • Sanofi
  • Shire
  • American Society of Transplant Surgeons

This publication has 31 references indexed in Scilit: